AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24183364
Drug: TA-ER (tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-ER (tramadol hydrochloride 75-mg/acetaminophen 650-mg)
Trial: 21512394
Drug: Tailored irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored irinotecan and S‐1 therapy (arm A)
Trial: 21512394
Drug: S‐1 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 monotherapy (arm B)
Trial: 17714197
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of picture of chocolate with chocolate in the mouth in cravers
Trial: 8961074
Drug: Moexipril 7.5
RxNorm normalized name: moexipril 7.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moexipril 7.5 mg once daily, increased to 15 mg once daily after 6 weeks if SDBP > 90 mm Hg
Trial: 8961074
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg twice daily, increased to 50 mg twice daily after 6 weeks if SDBP > 90 mm Hg
Trial: 2509064
Drug: Partial parenteral
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial parenteral plus enteral nutrition by tube feeding (PPN/EN)
Trial: 26077768
Drug: Partially defatted
RxNorm normalized name: rice bran, defatted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially defatted Brazil nut flour (13 g/day providing 227.5 μg of selenium/day)
Trial: 21663428
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after high-fat breakfast
Trial: 21663428
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after normal breakfast
Trial: 21663428
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after normal breakfast
Trial: 21663428
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after fasting
Trial: 19239703
Drug: Decremental PEEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decremental PEEP titration after ARM
Trial: 16107868
Drug: Vacuum constriction
RxNorm normalized name: Alstonia constricta bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum constriction device (VCD) used daily for 9 months (Group 1, N=74)
Trial: 16107868
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without any erectogenic treatment (Group 2, N=35)
Trial: 15204157
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (eutectic mixture of local anesthetics)
Trial: 8312148
Drug: Topical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agents for cutaneous infections in immunocompetent patients
Trial: 8312148
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy for recurrent vulvovaginal candidiasis and oroesophageal candida infections
Trial: 3552359
Drug: Sunitang (250,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitang (250, 500, and 1000 mg single oral doses)
Trial: 3552359
Drug: Sunitang (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitang (additional treatment alongside original medications)
Trial: 3552359
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (original medications only)
Trial: 29230716
Drug: Visnadine spray
RxNorm normalized name: visnadine
DrugBank: Visnadine (DB13355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visnadine spray (ReFeel® spray), 2 puffs in the vulvar area, 10 minutes before sexual stimulation, for 30 days (n=30)
Trial: 25452867
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg vitamin D3
Trial: 25452867
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg vitamin D3
Trial: 24785854
Drug: Continuous use
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous use of oral contraceptive pills (OCPs)
Trial: 24785854
Drug: Cyclic use
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic use of oral contraceptive pills (OCPs)
Trial: 8835619
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) at a dose of 5 mg/kg body weight in addition to insulin therapy
Trial: 8835619
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (insulin therapy only)
Trial: 31233129
Drug: Drug disposal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug disposal bag provision
Trial: 21292760
Drug: Placebo (as-needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (as-needed β-agonist)
Trial: 19681417
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tidal volume 10 ml/kg with no positive end-expiratory pressure)
Trial: 11576414
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and levamisole (combination treatment)
Trial: 8034203
Drug: O‐(beta‐hydroxyethyl)‐rutosides (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (HR) 250 mg 4 times daily (1 g/day), UK, n = 19 patients
Trial: 8034203
Drug: O‐(beta‐hydroxyethyl)‐rutosides (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 3 times daily (900 mg/day), FRG and Belgium, n = 55
Trial: 8034203
Drug: O‐(beta‐hydroxyethyl)‐rutosides (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 4 times daily (1,200 mg/day), The Netherlands, n = 30
Trial: 2883906
Drug: Oxprenolol 20
RxNorm normalized name: oxprenolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 20 mg
Trial: 786673
Drug: Oxprenolol 60
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol 60 mg
Trial: 786673
Drug: Dihydralazine 30
RxNorm normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine 30 mg
Trial: 786673
Drug: Hydrochlorothiazide 30
RxNorm normalized name: hydrochlorothiazide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 30 mg
Trial: 30950450
Drug: Various adjuvant
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various adjuvant treatments including locoregional and systemic therapies as per trials mentioned (MAGIC, Intergroup 0116, ACTS‐GC, CLASSIC, ARTIST, CRITICS)
Trial: 23211475
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone for 16 weeks
Trial: 21255472
Drug: Glucose (intragastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (intragastric infusion)
Trial: 21255472
Drug: Fructose (intragastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (intragastric infusion)
Trial: 21255472
Drug: Artificial Sweeteners
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial Sweeteners (AS: aspartame, acesulfame K, sucralose) (intragastric infusion)
Trial: 21255472
Drug: 2-deoxy-d-glucose (intragastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxy-d-glucose (intragastric infusion)
Trial: 15798546
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg) and succinylcholine (0.75 mg/kg)
Trial: 15798546
Drug: Etomidate (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.15 mg/kg) and succinylcholine (0.75 mg/kg)
Trial: 14514937
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mg once daily in the morning (09.00 hours)
Trial: 14514937
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mg once daily in the evening (21.00 hours)
Trial: 1631878
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride 0.5% solution, 10 ml/h
Trial: 1631878
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% solution, 10 ml/h
Trial: 31795359
Drug: Dose-dense weekly
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose-dense weekly paclitaxel (80 mg/m2) and low-dose triweekly cisplatin (20 mg/m2)
Trial: 24614605
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative therapy (OMT)
Trial: 16028386
Drug: Profenid administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profenid administered per rectum (100 mg)
Trial: 16028386
Drug: Profenid administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profenid administered intravenously (100 mg)
Trial: 12601511
Drug: Pelvicol implant
RxNorm normalized name: Delzicol
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pelvicol implant (n=74)
Trial: 12601511
Drug: Pelvicol implant
RxNorm normalized name: Delzicol
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pelvicol implant
Trial: 10684389
Drug: Positive patch
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive patch tests
Trial: 3861138
Drug: Intracervical PGE2-gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical PGE2-gel (0.5 mg)
Trial: 3861138
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal suppositories (2.0 mg)
Trial: 25298575
Drug: Nebivolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (2.5 mg, 5 mg, 10 mg)
Trial: 25298575
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (25 mg, 50 mg, 100 mg)
Trial: 21134821
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) plus cisplatin (FP) every three weeks
Trial: 12578781
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) 40 mg, administered orally, three times daily for 4 weeks
Trial: 12578781
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules filled with 40 mg fructose)
Trial: 10547209
Drug: Insulin added
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin added to glibenclamide therapy during phase I (4 months)
Trial: 10547209
Drug: GAD-antibody status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-antibody status
Trial: 1801688
Drug: GM-CSF after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF after chemotherapy
Trial: 1801688
Drug: GM-CSF as
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF as a priming agent 24 hours prior to chemotherapy
Trial: 29166336
Drug: Valganciclovir prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir prophylaxis (2 × 450 mg/d for 100 days)
Trial: 29166336
Drug: Preemptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive treatment (2 × 900 mg/d initiated at viral load of 400 CMV copies/mL or greater)
Trial: 29166336
Drug: Preemptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive treatment
Trial: 23796315
Drug: Exposure group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure group therapy
Trial: 25199046
Drug: Pre-treatment symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment symptom severity, race, age, gender
Trial: 23253305
Drug: Third wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third wave cognitive therapy
Trial: 23253305
Drug: Mentalization-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based therapy
Trial: 17507365
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both predictors (APC/h and max HR)
Trial: 12189364
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac tromethamine (intravenous)
Trial: 12189364
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ketorolac tromethamine (intramuscular or submucosal)
Trial: 12189364
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ketorolac tromethamine (at the surgical site)
Trial: 2197908
Drug: Fluconazole, 400
RxNorm normalized name: Fluconazole, 400 mg/200 mL-5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole, 400 mg/d for 10 weeks
Trial: 282084
Drug: Three distinct
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three distinct antihypertensive drugs, administered alone and combined two‐by‐two.
Trial: 31791209
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: voltage, 100 kVp, iodixanol, 270 mgI/mL
Trial: 31791209
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: voltage, 120 kVp; iohexol, 350 mgI/mL
Trial: 25973914
Drug: Bacillus clausii
RxNorm normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus clausii spores administered as lyophilized or liquid formulation
Trial: 25973914
Drug: Bacillus clausii
RxNorm normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus clausii spores (liquid suspension)
Trial: 23332366
Drug: Nebivolol (NEB)
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol (NEB) 5 mg/d, titrated to 20 mg/d
Trial: 21889878
Drug: Lurasidone 120
RxNorm normalized name: lurasidone 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 120 mg once daily
Trial: 23277250
Drug: Ziprasidone 80
RxNorm normalized name: ziprasidone 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 80 mg BID
Trial: 19498438
Drug: Efonidipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efonidipine (40 mg day(-1))
Trial: 19498438
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg day(-1))
Trial: 16979844
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose 30 Gy (dose/fraction 1.5 Gy, 16 patients)
Trial: 16979844
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose 25.5 Gy (dose/fraction 1.5 Gy, 62 patients)
Trial: 16979844
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose 20 Gy (dose/fraction 2 Gy, 69 patients)
Trial: 16979844
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose 26 Gy (dose/fraction 2 Gy, 29 patients)
Trial: 15003662
Drug: Autoclaved‐killed, whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoclaved‐killed, whole cell Leishmania amazonensis vaccine plus BCG adjuvant
Trial: 1775603
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitor HP 029 (doses not specified)
Trial: 29351310
Drug: Small-group intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-group intervention of seven weekly sessions of 120 min with a booster session after six weeks
Trial: 22159880
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000)
Trial: 22159880
Drug: Group BM
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group BM (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg)
Trial: 22159880
Drug: Group BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group BC (bupivacaine 0.166% with epinephrine 1:600,000 plus clonidine 1.0 μg/kg)
Trial: 22159880
Drug: Group BMC
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group BMC (bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg and clonidine 1.0 μg/kg)
Trial: 19889003
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy with added pioglitazone (45 mg)
Trial: 15762971
Drug: Single-dose cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefazolin (1 g intravenously before surgery)
Trial: 15762971
Drug: 1-day cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-day cefazolin (1 g intravenously before surgery and three more doses every 6 hr after surgery)
Trial: 11879210
Drug: Propofol-ephedrine combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-ephedrine combination
Trial: 7604787
Drug: Fluvastatin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin at 40 mg/day
Trial: 2196555
Drug: Codeine plus
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine plus 1 g of paracetamol t.i.d.
Trial: 2196555
Drug: Paracetamol t.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol t.i.d.
Trial: 27093610
Drug: GSK457 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK457 (40 g/day)
Trial: 17450046
Drug: Risperidone (1.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1.08 mg/day)
Trial: 9690573
Drug: Salmeterol powder
RxNorm normalized name: salmeterol Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol powder (50 microg twice daily)
Trial: 31778140
Drug: Ens-Grad machine
RxNorm normalized name: GRAd-COV2
DrugBank: GRAd-COV2 (DB16428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ens-Grad machine learning method for designing complementarity determining regions of human Immunoglobulin G antibodies
Trial: 26233289
Drug: N-palmitoylethanolamine (PEA)
RxNorm normalized name: N-palmitoylethanolamine
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-palmitoylethanolamine (PEA) and transpolydatin: 400 mg + 40 mg (1 tablet a day for 10 days from the 24th day of cycle)
Trial: 26233289
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet a day for 10 days from the 24th day of cycle)
Trial: 18719439
Drug: Dexmedetomidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.3 and 0.6 ng/ml)
Trial: 18719439
Drug: Dexmedetomidine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (up to 0.6 ng/ml)
Trial: 15772567
Drug: Soy supplements
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplements (Novasoy, 60 mg total isoflavone equivalents/day)
Trial: 10980842
Drug: Intravenous IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous IIb/IIIa blockade
Trial: 6253303
Drug: Hormones and
RxNorm normalized name: HORMONES AND RELATED AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormones and hormones and thiazide
Trial: 30183583
Drug: TACE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE therapy
Trial: 16310262
Drug: Standard HF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HF therapy
Trial: 26301344
Drug: Overall HF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall HF therapy
Trial: 23653910
Drug: Paediatric fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric fixed-dose combination granule for reconstitution (lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml)
Trial: 11008919
Drug: CagA protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CagA protein antibodies
Trial: 8341859
Drug: Fenoterol/Ipratropium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol/Ipratropium Bromide (F/IB; 0.1 mg/0.04 mg)